17,261 trials
Chronic Renal Failure
Primary: Change From Baseline in Daily Urine Volume — 169.2; 111.8; -259.9 mL
Prostate Cancer
Primary: Number of Participants Who Experience Grade 3 or Higher Acute Toxicities — 1; 1; 0 Participants
Primary Sclerosing Cholangitis (PSC)
Primary: Change From Baseline in MQC on Liver Biopsy at Week 96 — -0.5; 0.5; 0.0 percentage of MQC
Pancreatic Cancer
Primary: Recurrence Free Survival — 15.6 months
Type I Diabetes
Primary: Change From Baseline in HbA1c Levels — -0.12; 0.11 mmol/mol — p=0.0816
Atopic Dermatitis
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24 — -58.4; -72.2; -73.4; -69.2 percentage change — p=0.051
Multiple Myeloma
Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Non-Small Cell Lung Cancer
Primary: The Number of Patients With Stage IIIB/IV NSCLC Response Rate to the Combination Therapy of Sorafenib and Docetaxel/Carboplatin
Pancreatic Cancer
Primary: Surgical Exploration — 4; 6; 9 Participants
Asthma
Primary: Number of Participants With Events for Time to Loss of Asthma Control (LOAC) up to Week 52 - Cox Regression Analysis — 24; 24 Participants — p=0.5722
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Primary: Time for Viral Load to Drop Below Assay Quantification Limit (BQL) (Plaque Assay Analysis) — 46.1; 14.2; 5.1; 5.1 hours — p=<0.001
Estrogen Receptor Positive · Postmenopausal · Recurrent Fallopian Tube Carcinoma
Primary: Percentage of Patients Alive and Free of Progression at 12 Weeks (PFS12) — 52.6; 57.9 percentage of patients
Primary Sjögren's Syndrome
Primary: Number of Participants With Primary Sjögren's Syndrome With Adverse Events and Death up to Day 85 — 20; 8; 1; 0 count of participants
Glaucoma and Ocular Hypertension
Primary: Summary of Change From Baseline Average Intraocular Pressure Diurnal Measurement by Treatment Group Population (Cohort 1) — -5.10; -6.65; -3.17; -5.67 mm Hg — p=<0.001
Metabolism - Cerebral Energy
Primary: Magnetic Resonance Spectroscopy (MRS) Will Measure a Change in Cerebral Energy Function in Brain Tissue — .011; .007; .009; .006 Difference in metabolite amplitude